Evidence That Could Have Changed the Decision Earlier
- 30 minutes ago
- 1 min read
The most expensive mistake in drug development may happen before the Phase III failure.
Not because the science was wrong.
But because the evidence was never strong enough to challenge the assumptions behind the next decision.
A promising biomarker.
A positive early signal.
A biologically compelling mechanism.
A seemingly appropriate patient population.
These can all move a program forward while critical uncertainties remain unresolved.
And when Phase III fails, those uncertainties suddenly become visible, expensive, and much harder to address.
Our latest Evidence Brief examines what could have been learned earlier across four clinical development programs, and asks a different question:
What evidence could have changed the decision while there were still options?
From responder heterogeneity and disease timing to endpoint selection and real-world applicability, the opportunity is not to predict failure in hindsight.
It is to generate the evidence that helps teams challenge assumptions, preserve strategic options, and make better decisions before uncertainty becomes expensive.
Read the full Evidence Brief below.
